EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Association of genetic variations of 3′-UTR in clopidogrel pharmacokinetic-relevant genes with clopidogrel response in Han Chinese patients with coronary artery disease

Dongjie Li, Boyu Xiang, Jingxuan Peng, He Li, Liming Peng, Xiaoping Chen

European Journal of Pharmaceutical Sciences · 2024

DOI: 10.1016/j.ejps.2024.106830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutical Sciences, 2024. Verfasst von Dongjie Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Xiangya Hospital, Central South University, Changsha, China; Department of Clinical Pharmacology, Xiangya Hospital, Central So…. Hauptthemen laut MEDLINE: Clopidogrel, Platelet Aggregation Inhibitors, Coronary Artery Disease, 3' Untranslated Regions. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Hunan Province, Fundamental Research Funds for Central Universities of the Central South University, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dual antiplatelet therapy with aspirin and clopidogrel has reduced ischemic vascular events significantly. Genetic influence, especially those in clopidogrel pharmacokinetic-relevant genes partially accounts for interindividual pharmacodynamic variability of clopidogrel. However, most studies have concentrated on the genetic variations in introns, exons, or promoters of the candidate genes, and the association between genetic variations in 3'-UTR in clopidogrel pharmacokinetic-relevant genes and clopidogrel response is unknown. In our study, ten different algorithms were applied to pick potential miRNAs targeting the clopidogrel pharmacokinetic-relevant genes. Furthermore, the correlation between miRNA expression profiles and mRNA expression of corresponding clopidogrel pharmacokinetic-relevant genes was analyzed. Through comprehensive analysis, including bioinformatics prediction and correlation analysis of miRNA and mRNA expression profiles, miR-218-5p and miR-506-5p were supposed to regulate the expression of PON1 via binding with its 3'-UTR. Moreover, PON1 rs854551 and rs854552 were located in miRNA recognizing sequences and may serve as potential miRSNPs possibly affecting PON1 expression. The rs854552 polymorphism was genotyped and platelet reactivity index (PRI) indicative of clopidogrel response was measured in 341 Chinese coronary artery disease (CAD) patients 24 h after administration of 300 mg clopidogrel. Our results showed that PON1 rs854552 had a significant influence on PRI in CAD patients, especially in patients with CYP2C19 extensive metabolic phenotype. In conclusion, PON1 rs854552 polymorphisms may affect clopidogrel response. Bioinformatics prediction followed by functional validation could aid in decoding the contribution of unexplained variations in the 3'-UTR in drug-metabolizing enzymes on clopidogrel response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelPlatelet Aggregation InhibitorsCoronary Artery Disease3' Untranslated RegionsMicroRNAsHumansMaleFemaleMiddle AgedAryldialkylphosphatasePolymorphism, Single NucleotideAgedGenotypeEast Asian People

Stichwörter der Autor:innen

Bioinformatics predictionClopidogrel responsePlatelet reactivity indexmiRNAmiRSNPs

Substanzen

ClopidogrelPlatelet Aggregation Inhibitors3' Untranslated RegionsMicroRNAsPON1 protein, humanAryldialkylphosphatase

Autor:innen und Institutionen

  • Department of Urology, Xiangya Hospital, Central South University, Changsha, China; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China; Institute of Clinical Pharmacology, C…
  • Department of Urology, Xiangya Hospital, Central South University, Changsha, China.
  • Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China.
  • Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China;…

Förderung

  • Natural Science Foundation of Hunan Province
  • Fundamental Research Funds for Central Universities of the Central South University
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Li, D., Xiang, B., Peng, J., Li, H., Peng, L., & Chen, X. (2024). Association of genetic variations of 3′-UTR in clopidogrel pharmacokinetic-relevant genes with clopidogrel response in Han Chinese patients with coronary artery disease. European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2024.106830

Vancouver

Li D, Xiang B, Peng J, Li H, Peng L, Chen X. Association of genetic variations of 3′-UTR in clopidogrel pharmacokinetic-relevant genes with clopidogrel response in Han Chinese patients with coronary artery disease. European Journal of Pharmaceutical Sciences. 2024. doi:10.1016/j.ejps.2024.106830

BibTeX
@article{Li2024,
  author = {Li, Dongjie and Xiang, Boyu and Peng, Jingxuan and Li, He and Peng, Liming and Chen, Xiaoping},
  title = {Association of genetic variations of 3′-UTR in clopidogrel pharmacokinetic-relevant genes with clopidogrel response in Han Chinese patients with coronary artery disease},
  journal = {European Journal of Pharmaceutical Sciences},
  year = {2024},
  doi = {10.1016/j.ejps.2024.106830}
}
Kostenlos starten →